FATE NK100

Drug Profile

FATE NK100

Alternative Names: Natural killer cell therapy - Fate Therapeutics

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator Fate Therapeutics
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 13 Mar 2017 Fate Therapeutics and Masonic Cancer Center plan a Phase I trial for Acute myeloid leukaemia (Late-stage disease, Combination therapy, Second-line therapy or greater) in USA (NCT03081780)
  • 13 Mar 2017 US FDA approves IND application for FATE NK100 in Acute myeloid leukaemia (Late-stage disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top